Next-Generation Antibodies Market To Be Worth $11.6bn In 2020, A New Visiongain Study Predicts

07 September 2018
Pharma

A new report by visiongain, published in April 2016, forecasts that the worldwide next-generation antibodies market will generate $11.6 billion in 2020. That revenue forecast and others appear in Next-Generation Antibody Therapies Market Forecast 2016-2026: Explore Developments and Sales Potentials for ADCs, Engineered Antibodies, ALPs, Bispecific and Biosimilar Agents.

Visiongain is a business information publisher and consultancy based in London, UK. Its purpose is to help companies and other organisations assess the potentials of industries and market in healthcare and other fields.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said:
“Next-generation antibody therapies are treatments based on antibodies that have been engineered or otherwise designed to have advantages over simple monoclonal antibodies. Next-generation antibodies are establishing themselves in the market, seven years after the current crop of novel therapies first reached the market with the approval of Kalbitor and Removab in 2009.

“Sales of Adcetris and Kadcyla constitute the majority of revenues in the market in 2016, but over the next ten years rapid growth will stem from the launch of biosimilar drugs, and later from new engineered and bispecific antibody therapies. A strong and varied R&D pipeline will propel this market to new heights from 2016 to 2026.”

First visiongain’s new study provides revenue forecasts to 2026 for five submarkets and the overarching world market:

• Antibody-drug conjugates
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and ALPs
• Biosimilar antibodies.

In addition that investigation shows revenue forecasts to 2026 for seven drugs:

• Adcetris
• Kadcyla
• Gazyva/Gazyvaro
• Poteligeo
• Removab
• Blincyto
• Kalbitor.

That analysis also shows revenue forecasts to 2026 for four regional markets:

• US
• EU5 group
• Asia-Pacific region
• Latin America
• Rest of the world.

The new report discusses forces stimulating sales growth over the next ten years, as well as forces restraining that industry and market. That work also shows interviews with three companies – Ablynx, arGEN-X and Mersana Therapeutics.

Next-Generation Antibody Therapies Market Forecast 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever